Going Early For Maximum Long Term Value From Medtech Deals
For Medtech Deal-Makers The Best Opportunities Must Be Developed Well In Advance Of M&A
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
